Physician profile
Malini Mathur
NPI 1871751610
$3,647.26
in general payments reported to CMS, 2019-2025
28 companies · $511 in 2025
The $511 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $758 · 2020: $283 · 2021: $347 · 2022: $580 · 2023: $656 · 2024: $514 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,644 · Education: $35.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.36 |
| Education | $35.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,345.93 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $581.95 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $227.26 | 2019-2025 | Gattex, Eohilia |
| Daiichi Sankyo INC. | $204.60 | 2021-2025 | Injectafer |
| Pfizer INC. | $186.66 | 2019-2025 | |
| Janssen Biotech, INC. | $185.25 | 2019-2025 | Simponi, Stelara, Simponi Aria |
| Merck Sharp & Dohme LLC | $120.02 | 2020-2024 | Dificid |
| Gilead Sciences, INC. | $119.99 | 2023 | Epclusa |
| Ardelyx, INC. | $89.30 | 2023-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $82.75 | 2021-2022 | |
| Qol Medical, LLC | $68.78 | 2021-2023 | Sucraid |
| Celgene Corporation | $60.47 | 2021-2022 | |
| Celltrion USA INC. | $55.38 | 2024 | Zymfentra, Vegzelma |
| Intercept Pharmaceuticals, INC. | $48.67 | 2019-2023 | Ocaliva |
| Novo Nordisk INC | $26.73 | 2025 | Wegovy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $24.79 | 2019 | |
| Octapharma USA, INC. | $23.94 | 2019 | |
| Braintree Laboratories, INC. | $23.12 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $22.81 | 2020 | |
| Lilly USA, LLC | $19.71 | 2025 | |
| Mallinckrodt Hospital Products INC. | $18.46 | 2024 | Terlivaz |
| Ipsen Biopharmaceuticals, INC | $18.23 | 2025 | Iqirvo |
| Alfasigma USA, INC. | $16.86 | 2020 | |
| Endogastric Solutions, INC | $16.52 | 2024 | Esophyx |
| Cook Medical LLC | $15.85 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.77 | 2024 | Voquezna |
| Redhill Biopharma INC. | $14.64 | 2020 | |
| Genzyme Corporation | $13.82 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malini Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.